Xilio Therapeutics Presents Promising Phase 2 Data for Vilastobart in Combination with Atezolizumab in Metastatic MSS Colorectal Cancer

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo...

January 23, 2025 | Thursday | News
Stuart Therapeutics Completes Phase III Study of ST-100 for Dry Eye Disease, Topline Data Expected in February 2025

Stuart Therapeutics, Inc. (Stuart), a clinical-stage drug platform company developing novel therapies for ophthalmic diseases,  announced last patient...

January 23, 2025 | Thursday | News
Antennova Presents Promising Phase I/II Data for ATN-022 in Advanced Gastric Cancer at ASCO GI 2025

 Antennova, a clinical-stage biotech company focused on oncology announced the presentation of latest data from its Phase I/II CLINCH s...

January 23, 2025 | Thursday | News
Sanofi’s Opella Achieves FDA Approval to Initiate OTC Cialis Use Trial

Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned a...

January 21, 2025 | Tuesday | News
Junshi Biosciences Partners with LEO Pharma to Launch Toripalimab in Europe

Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati...

January 21, 2025 | Tuesday | News
Valneva Announces Strong One-Year Phase 3 Results for IXCHIQ®, Its Single-Dose Chikungunya Vaccine in Adolescents

 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced additional positive Phase 3 results in adolescents for it...

January 21, 2025 | Tuesday | News
Concept Medical Announces Successful Completion of Patient Enrollment in Landmark SirPAD Trial for Peripheral Arterial Disease Treatment

CMI, a global leader in innovative drug delivery technologies for vascular procedures, is proud to announce that patient enrollment in the SirPAD trial has...

January 21, 2025 | Tuesday | News
Novo Nordisk Announces Positive Results from STEP UP Phase 3b Trial for Semaglutide 7.2 mg in Obesity Treatment

Novo Nordisk  announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial i...

January 20, 2025 | Monday | News
MediBeacon's TGFR System Receives FDA Approval for Kidney Function Assessment

MediBeacon Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR for the assessment of kidney fu...

January 20, 2025 | Monday | News
IMPACT Therapeutics' Senaparib Capsules Receive NMPA Approval for Maintenance Treatment of Advanced Ovarian Cancer in China

 IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on s...

January 20, 2025 | Monday | News
Fermion and Simcere Partner to Advance Innovative SSTR4 Agonist for Pain Management in Greater China

Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain ...

January 20, 2025 | Monday | News
OS Therapies Announces Positive Phase 2b Results for OST-HER2 in Preventing Recurrence of Lung Metastatic Osteosarcoma

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, ...

January 17, 2025 | Friday | News
Silexion Therapeutics Reveals Synergistic Efficacy of SIL-204 in Combination with Chemotherapy for Pancreatic Cancer

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNA...

January 17, 2025 | Friday | News
Solid Biosciences Advances Toward Transformative Genetic Medicines with Expanded Pipeline and New Clinical Milestones

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines fo...

January 17, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close